JSAM
ALNY icon

J. Safra Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

J. Safra Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$940K Buy
3,122
+509
+19% +$154K 0.04% 125
2026
Q1 		$865K Buy
2,613
+974
+59% +$331K 0.05% 114
2025
Q4 		$652K Buy
1,639
+244
+17% +$108K 0.03% 139
2025
Q3 		$636K Buy
1,395
+1,352
+3,144% +$551K 0.04% 99
2025
Q2 		$14K Buy
43
+2
+5% +$553 ﹤0.01% 269
2025
Q1 		$11.1K Buy
41
+34
+486% +$8.74K ﹤0.01% 290
2024
Q4 		$1.65K Hold
7
– – ﹤0.01% 305
2024
Q3 		$1.92K Buy
+7
New +$1.82K ﹤0.01% 267
2023
Q4 		– Sell
-2
Closed -$354 – 128
2023
Q3 		$354 Hold
2
– – ﹤0.01% 103
2023
Q2 		$380 Hold
2
– – ﹤0.01% 97
2023
Q1 		$400 Hold
2
– – ﹤0.01% 98
2022
Q4 		$0 Buy
+2
New +$427 ﹤0.01% 72

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Safra Asset Management's ALNY Position: Q2 2026 in Review

J. Safra Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 19% in Q2 2026, buying an estimated $154K and bringing the position to 3,122 shares worth $940K. The position accounts for 0.04% of the portfolio, ranked #125.

J. Safra Asset Management first reported a position in ALNY in Q4 2022 and has held it in 12 quarters since. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • J. Safra Asset Management held 3,122 shares of Alnylam Pharmaceuticals worth $940K as of Q2 2026.
  • J. Safra Asset Management bought 509 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $154K.
  • Alnylam Pharmaceuticals made up 0.04% of J. Safra Asset Management's portfolio in Q2 2026, its #125 holding.
  • J. Safra Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.